Of note, loss of KRAS control and subsequent RAF-ERK-activation as a consequence of the downregulated, strongly tumorsuppressive miR-622 was recently demonstrated by our group to induce sorafenib resistance in HCC [6,10,22]. The gene discussed is KRAS; the disease is hepatocellular carcinoma.